20(R)-Ginsenoside Rg3 Water Solubility via Cyclodextrin Mediator
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The bioavailability of 20(R)-ginsenoside Rg3 is low due to its insolubility in water, limiting its clinical efficacy, and existing methods for dissolving it in water, such as the ginsenoside Rg3 hydroxypropyl-β-cyclodextrin clathrate, face challenges like residual organic solvent issues and incomplete transformation, leading to increased production costs and reduced utilization rates.
Innovation Solution
A pharmaceutical composition of 20(R)-ginsenoside Rg3 is developed using deoxycholic acid, sodium dodecylsulphate, and various cyclodextrins, with specific weight ratios and preparation processes that allow for complete dissolution in water, eliminating residual solvents and achieving 100% transformation, thereby enhancing bioavailability and reducing production costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If 20(R)-ginsenoside Rg3 is dissolved in water using hydroxypropyl-β-cyclodextrin clathrate, then water solubility is improved, but residual organic solvent remains and transformation is incomplete
Solution Approach 1:
The patent uses hydroxypropyl-β-cyclodextrin as an intermediary substance to form a clathrate complex with 20(R)-ginsenoside Rg3. The cyclodextrin acts as a mediator that encapsulates the hydrophobic ginsenoside within its hydrophilic cavity structure, enabling water solubility while maintaining complete transformation without residual organic solvent.
Solution Approach 2:
The patent optimizes the molar ratio parameter between 20(R)-ginsenoside Rg3 and hydroxypropyl-β-cyclodextrin to achieve complete transformation. By controlling this critical parameter within a specific range, the method ensures 100% transformation efficiency while maintaining water solubility and eliminating residual organic solvent.
2Quantity of substance
If 20(R)-ginsenoside Rg3 is dissolved in water using hydroxypropyl-β-cyclodextrin clathrate, then water solubility is improved, but production cost increases due to incomplete transformation
Solution Approach 1:
The patent optimizes the molar ratio parameter between 20(R)-ginsenoside Rg3 and hydroxypropyl-β-cyclodextrin to achieve complete transformation. By controlling this critical parameter within a specific range, the method ensures 100% transformation efficiency while maintaining water solubility and eliminating residual organic solvent.
Solution Approach 2:
The patent uses hydroxypropyl-β-cyclodextrin as an intermediary substance to form a clathrate complex with 20(R)-ginsenoside Rg3. The cyclodextrin acts as a mediator that encapsulates the hydrophobic ginsenoside within its hydrophilic cavity structure, enabling water solubility while maintaining complete transformation without residual organic solvent.
3Ease of operation
If 20(R)-ginsenoside Rg3 is used in oral preparation, then administration is simplified, but bioavailability is low due to water insolubility
Solution Approach 1:
The patent uses hydroxypropyl-β-cyclodextrin as an intermediary substance to form a clathrate complex with 20(R)-ginsenoside Rg3. The cyclodextrin acts as a mediator that encapsulates the hydrophobic ginsenoside within its hydrophilic cavity structure, enabling water solubility while maintaining complete transformation without residual organic solvent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a 100% bioavailability of 20(R)-ginsenoside Rg3, significantly improving its absorption and reducing treatment costs, with enhanced efficacy in cancer treatment and other therapeutic applications.
Implementation Method 1
A pharmaceutical composition of 20(R)-ginsenoside Rg3 is developed using deoxycholic acid, sodium dodecylsulphate, and various cyclodextrins, with specific weight ratios and preparation processes that allow for complete dissolution in water
Data Source
AI summary
A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5˜10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1˜30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40˜100° C., the ratio of these two is 1:1˜300, add water after the solvent is recycled under reduced pressure; another kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution contains 0.1˜2 mg/ml of 20 (R) of the ginsenoside Rg3, the preparation: add 0.1˜5% of ginsenoside solution to 20˜65% of adjuvant B{circle around (3)}{circle around (4)} at the temperature of 60˜100° C., main material to adjuvant B=1:100˜400, add water after the solvent is recycled under reduced pressure. The above 20 (R) ginsenoside Rg3 composition aqueous solution and the powder after lyophilization can be used to prepare injectable, oral administration and external use, and the bioactivity of these preparations is high, and with the actions of anti cancer, efficacy potentiation and toxicity attenuation effects of the combined chemical or radiation therapy of tumor, enhancement of human immune functions, improvement of human memory, anti fatigue, and detumescence, pain relieving.